Hengrui, Glenmark ink ADC deal; Rome Therapeutics to seek 'strategic options'

Plus, news about Manas AI, Dewpoint Therapeutics, Cyclerion Therapeutics, Monopar Therapeutics and Eupraxia: 🇨🇳 Hengrui hands Glenmark select licensing rights to its ADC: In a deal worth up to $1.1 billion ...